-
Isn't the risk of drug co-production quality related to the residue content and activity?
Time of Update: 2021-12-07
If it is difficult to clean, it is easy to have the residue of the previous batch of materials, which will become an impurity in the next product .
-
Hengrui, CSPC, Qilu and others take the lead in fighting the "new drug war", and medical innovation blossoms at multiple levels
Time of Update: 2021-12-07
The "New Drug War" stormtrooper represented by Hengrui, CSPC, and Qilu Hengrui is a company that attaches great importance to R&D investment among many domestic pharmaceutical companies.
-
Vice President of AstraZeneca China will leave and join BeiGene
Time of Update: 2021-12-07
Recently, it was reported that Du Haochen, vice president of AstraZeneca China and head of the county business department, decided to leave the company due to personal reasons.
-
Ma Xingtian, the former chairman of Kangmei Pharmaceutical, was sentenced to 12 years in prison in the first instance
Time of Update: 2021-12-07
According to Xinhua News Agency, on November 17, the Intermediate People's Court of Foshan City, Guangdong Province publicly pronounced on the case of 12 people including the former chairman and general manager of Kangmei Pharmaceutical, including Ma Xingtian, for manipulating the securities market .
-
Novavax submits biologics license application to South Korea
Time of Update: 2021-12-07
NVX-CoV2373 is created using Novavax recombinant nanoparticle technology to produce antigens derived from coronavirus spike protein, and Novavax’s patented saponin-based Matrix-M™ adjuvant is used to enhance immune response and stimulate high levels of neutralization Antibody .
-
Auzong Bio's "Edaravone Oral Preparation" Obtained FDA Orphan Drug Designation
Time of Update: 2021-12-07
According to the press release of Aozong Bio, TTYP01 oral tablets have better safety than edaravone injection by intravenous drip, and patients can choose to increase the dose of the drug to achieve better clinical effects .
-
The performance of the specialty API sector has been eye-catching recently. How sustainable is the market?
Time of Update: 2021-12-07
In the interpretation of this market, the fundamental support lies in the bottoming of performance, and the inflection point of the industry’s prosperity is superimposed on the new business catalysis of individual stocks; at the capital level, there is a need to switch from high valuations to low valuations; After the release of the "Notice on the Implementation Plan for the High-Quality Development of the Industry" policy document, it entered a small climax .
-
Lepu Bio-Oncolytic Virus New Drug Approved for Clinical Treatment of Non-muscle Invasive Bladder Cancer
Time of Update: 2021-12-07
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiRecently, the official website of CDE showed that the clinical trial application of Lepu Bio/CG Oncology's CG0070 injection has been approved by the National Medical Products Administration (NMPA), and a phase I clinical study for the treatment of non-muscular invasive bladder cancer will be carried out in China .
-
18 well-known pharmaceutical company executives change in half a month involving 4 chairman
Time of Update: 2021-12-07
Han Jing serves as Chief Commercial Officer of Corning JerryHan Jing serves as Chief Commercial Officer of Corning JerryOn November 2, Corning Jerry issued an announcement stating that Han Jing has been appointed as the chief commercial officer, who is mainly responsible for the company's commercialization and promotion, and will directly report to the chairman and president Dr.
-
Catch up with Farxiga/Jardiance, Johnson & Johnson releases Phase III clinical results of hypoglycemic drug Invokana
Time of Update: 2021-12-07
CompilenewbornRecently, Phase 3 data released at the 2021 Virtual Science Conference of the American Heart Association (AHA) showed that Johnson & Johnson’s type 2 diabetes drug Invokana (canagliflozin) has helped improve the symptoms of heart failure in patients, regardless of whether they have Diabetes .
-
Many new pharmaceutical stocks broke!
Time of Update: 2021-12-07
In addition to Shamrock Bio, on November 11, Hualan shares also performed poorly on the first day of listing on the Shenzhen Stock Exchange’s ChiNext, directly falling below the issue price .
-
In November, more than 40 drug registration certificates have been cancelled
Time of Update: 2021-12-07
At the same time, the "elimination competition" of the pharmaceutical industry is expected to accelerate, and a large number of drug registration certificates will also be cancelled .
-
Two departments issued implementation plans to promote the high-quality development of the API industry
Time of Update: 2021-12-07
(Guo Ting) Recently, the National Development and Reform Commission and the Ministry of Industry and Information Technology jointly issued the "Implementation Plan for Promoting the High-quality Development of the API Industry" (hereinafter referred to as the "Plan") .
-
"The war will start" for APIs?
Time of Update: 2021-12-07
Figure 2 Analysis of changes in operating income and profit of China's chemical raw materialsData source: PDBFigure 3 Distribution of my country's API companiesData source: Ping An of ChinaIn general, China's API production technology and quality level are gradually improving, and it is transitioning from the stage of producing only low-end bulk APIs to the stage of producing higher-end specialty APIs and patented APIs .
-
Janssen announces that the innovative targeted drug Zhaoke (R) has been approved for first-line indications in China
Time of Update: 2021-12-07
, a subsidiary of Johnson & Johnson in China, announced today that its innovative targeted drug Zhaoke® (Daletuzumab injection, English trade name) : DARZALEX®, English generic name: Daratumumab Injection) was approved by the National Medical Products Administration, and combined with lenalidomide and dexamethasone or combined with bortezomib, melphalan and prednisone is not suitable for the treatment of autologous stem cells Adult patients with newly diagnosed multiple myeloma transplanted .
-
Yaohua Medicine's rare blood disease drug Besremi obtains FDA approval for listing
Time of Update: 2021-12-07
The injected drug is approved for the treatment of adult patients with polycythemia vera, a rare blood disease that causes blood to thicken and affects approximately 6,200 people in the United States each year .
-
Facing stricter supervision and fierce competition, medical insurance pharmacies are actively integrating into new business formats
Time of Update: 2021-12-07
In this context, data from leading retail pharmacies can be found that in the first half of this year alone, the six major chain medical insurance designated stores accounted for more than 80% of the total.
-
The 2021 edition of the basic medicine catalog management method is released!
Time of Update: 2021-12-07
The types and quantities of adjustments should be determined based on the following factors: (1) China's basic medical and health service needs and basic medical security level changes; (2) China's disease spectrum changes; (3) Adverse drug reaction monitoring and evaluation; (4) Drug use monitoring And clinical comprehensive evaluation; (5) Evidence-based medicine and pharmacoeconomic evaluation of marketed drugs; (6) Other conditions specified by the National Essential Medicines Working Committee .
-
Under the intensified competition in the PD-1 market, domestic pharmaceutical companies are speeding up going overseas
Time of Update: 2021-12-07
In fact, in the same year, Livzonumab had already licensed the recombinant humanized anti-PD-1 monoclonal antibody (LZM009) for injection with independent intellectual property rights to BPTx for a paid and non-exclusive license for the development of new PD-1 targeting Immune cytokines (PD-1 ICs), and authorized LZM009 to BPTx for the development and commercialization of PD-1 ICs drugs in regions other than Greater China .
-
The total output value of the biological manufacturing industry in the Chengdu High-tech Zone has increased by more than 14%
Time of Update: 2021-12-07
For example, on November 5, Shamrock Bio was officially listed on the main board of the Stock Exchange of Hong Kong Limited, marking that Chengdu’s listed companies in the field of biomedicine have added "new faces"; on November 3, Yuanda Shuyang Pharmaceutical Human Fibrinogen The product has obtained the drug registration certificate issued by the National Medical Products Administration.
